Table 1 Characteristics of subjects with total high-grade salivary gland cancers (n = 124) and resectable high-grade salivary gland cancers (n = 103)
Characteristics | No. | % |
|---|---|---|
Total high-grade salivary gland cancers (n = 124) | ||
Age [years; median (range)] | 61 (31–89) | |
Gender (Male/Female) | 95/29 | 76.6/23.4 |
Tumor site | ||
Parotid gland | 84 | 67.7 |
Submandibular gland | 38 | 30.6 |
Sublingual gland and minor salivary gland | 2 | 1.6 |
T classification | ||
T1 | 20 | 16.1 |
T2 | 44 | 35.5 |
T3 | 23 | 18.5 |
T4 | 37 | 29.8 |
N classification | ||
N0 | 63 | 50.8 |
N1 | 10 | 8.1 |
N2–3 | 51 | 41.1 |
M classification | ||
M0 | 109 | 87.9 |
M1 | 15 | 12.1 |
AJCC TNM stage | ||
I | 14 | 11.3 |
II | 24 | 19.4 |
III | 16 | 12.9 |
IV | 70 | 56.5 |
Pathological diagnosis | ||
Salivary duct carcinoma | 74 | 59.7 |
Squamous cell carcinoma, primary* | 13 | 10.5 |
Adenoid cystic carcinoma, solid type | 12 | 9.7 |
Mucoepidermoid carcinoma, high-grade | 9 | 7.3 |
Adenocarcinoma, high-grade | 6 | 4.8 |
Atypical high-grade carcinoma | 3 | 2.4 |
Carcino-sarcoma, high-grade | 4 | 3.2 |
Poorly differentiated carcinoma | 3 | 2.4 |
Treatment modalities | ||
Surgery alone | 13 | 10.5 |
Surgery + adjuvant radiation | 62 | 50.0 |
Surgery + adjuvant radiation + chemotherapy | 28 | 22.6 |
Initial non-surgical local treatment (radiation or chemoradiation) | 3 | 2.4 |
Chemotherapy or palliative treatment | 18 | 14.5 |
Clinical outcomes | ||
Disease-specific death | 39 | 31.5 |
Event-free follow-up period [months; median (range)] | 109 [2–188] | |
All-cause death | 44 | 35.5 |
Resectable high-grade salivary gland caners (n = 103) | ||
Surgery for primary tumor | ||
R0 resection (cancer cells absent at the resection margin) | 97 | 94.2 |
R1 resection (cancer cells present at the resection margin) | 6 | 5.8 |
Neck dissection | ||
No | 31 | 30.1 |
Selective neck lymph node dissection | 30 | 29.1 |
Comprehensive neck lymph node dissection | 42 | 40.8 |
Pathological risk factors | ||
Perineural invasion (Y/N) | 13/90 | 12.6/87.4 |
Lymphovascular invasion (Y/N) | 16/87 | 15.5/84.5 |
Extra-parenchymal (Extra-glandular) extension of tumor (Y/N) | 45/58 | 43.7/56.3 |
Extra-capsular spread of lymph node metastasis (Y/N) | 26/77 | 25.2/74.8 |
Clinical outcomes | ||
Recurrence | 40 | 38.8 |
Recurrence-free period [months; median (range)] | 109 [2–188] | |
Disease-specific death | 27 | 26.2 |
Event-free follow-up period [months; median (range)] | 123 [2–188] | |